3.8 Article

Application of Health Technology Assessment for Oncology Care in India: Implications for Ayushman Bharat Pradhan Mantri Jan Aarogya Yojana

Journal

INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY
Volume 42, Issue 5, Pages 479-483

Publisher

THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0041-1740536

Keywords

cost-effectiveness; health economics; health insurance; Health Technology Assessment; medical oncology; priority setting; universal health coverage

Categories

Ask authors/readers for more resources

Efficiency in a health system requires balancing costs and benefits, with evidence-informed decisions made through Health Technology Assessment (HTA). In multi-payer systems like India, inequities in healthcare utilization exist, but initiatives like Ayushman Bharat Pradhan Mantri Jan Aarogya Yojana can help ensure equity by reducing financial barriers.
A health system is considered efficient when it provides maximum health gains to the population from the available resources. Newer drugs, diagnostics and treatment strategies aim to improve the health of the population, however, they come at an increased cost. Therefore, for an efficient health system, it needs to be decided if the extra cost being incurred is justified to achieve the extra health gains. In this regard, health technology assessment (HTA) helps to make evidence informed decisions by evaluating relative cost and benefits of the available interventions. Economic evidence generated by HTA can also be used in framing standard treatment guidelines (STGs) for high-cost cancer care. In multi-payer systems like India, the decisions regarding the clinical management of patients are taken based on the patients' ability to pay, which creates inequities in utilization of healthcare. Ayushman Bharat Pradhan Mantri Jan Aarogya Yojana (AB PM-JAY) offers an opportunity to ensure equity as it reduces financial barriers, besides having a potential to affect efficiency by including only cost-effective interventions in the benefit package. As a result, informed clinical decisions based upon HTA evidence can make cancer treatment more efficient, equitable and affordable for the patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available